Nu-Med Plus (NUMD) Amortization of Deferred Charges (2013 - 2022)

Nu-Med Plus (NUMD) reported Amortization of Deferred Charges of $3084.0 for Q1 2022, down 89.96% sequentially from $30716.0 in Q1 2014.

Nu-Med Plus (NUMD) Amortization of Deferred Charges (2013 - 2022) Analysis & Trends

Nu-Med Plus (NUMD) has 3 years of Amortization of Deferred Charges data on file, last reported at $3084.0 in Q1 2022.

For the quarter ending Q1 2022, Amortization of Deferred Charges changed N/A year-over-year to $3084.0; the trailing twelve-month figure through Mar 2022 stood at $3084.0 (changed N/A YoY), and the FY2022 full-year result was $8222.0, changed N/A from the prior year.
Amortization of Deferred Charges fell to $3084.0 in Q1 2022, from $30716.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $3084.0 in Q1 2022 to a low of $3084.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Nu-Med Plus	1.67 Mn	1.67 Mn	-

Download Data